These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 38402457

  • 1. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
    Sung HL, Hung CY, Tung YC, Lin CC, Tsai TH, Huang KH.
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457
    [Abstract] [Full Text] [Related]

  • 2. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

  • 3. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ.
    Cardiovasc Diabetol; 2018 Jun 23; 17(1):91. PubMed ID: 29935543
    [Abstract] [Full Text] [Related]

  • 4. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
    Longo M, Caruso P, Scappaticcio L, Maiorino MI, Bellastella G, Capuano A, Esposito K, Giugliano D.
    Diabetes Obes Metab; 2024 Apr 23; 26(4):1492-1501. PubMed ID: 38234208
    [Abstract] [Full Text] [Related]

  • 5. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2235995. PubMed ID: 36219443
    [Abstract] [Full Text] [Related]

  • 6. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.
    Ziser KED, Wood S, Tan GSQ, Morton JI, Shaw JE, Bell JS, Ilomaki J.
    J Diabetes; 2024 Apr 03; 16(4):e13507. PubMed ID: 38599885
    [Abstract] [Full Text] [Related]

  • 7. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM.
    Kidney Int; 2024 Mar 03; 105(3):618-628. PubMed ID: 38101515
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Jung C, Park S, Kim H.
    PLoS One; 2023 Mar 03; 18(11):e0294423. PubMed ID: 37992029
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z, Sun J, Han R, Fan D, Dong X, Luan Z, Xiang R, Zhao M, Yang J.
    Diabetes Obes Metab; 2018 Jan 03; 20(1):113-120. PubMed ID: 28656707
    [Abstract] [Full Text] [Related]

  • 12. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
    Kohsaka S, Takeda M, Kidani Y, Yajima T.
    Diabetes Obes Metab; 2021 Apr 03; 23 Suppl 2():28-39. PubMed ID: 33835640
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, Chang Y, Byrne CD, Shin JY.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2349856. PubMed ID: 38153732
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.